Principal Investigator
Gilberto Lopes
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240093
Clinical Trial Summary
A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients with Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
+1 (954) 8177628